Patent Application
20170128551
This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of patients suffering from a limited range of muscle extension, in particular from flexion contracture, in particular flexion contracture of the knee, and more particularly uses for the treatment of such patients having experienced a total knee arthroplasty.
Clostridium is a genus of anaerobe gram-positive bacteria, belonging to the Firmicutes. Clostridium consists of around 100 species that include common free-living bacteria as well as important pathogens, such as Clostridium botulinum and Clostridium tetani. Both species produce neurotoxins, botulinum toxin and tetanus toxin, respectively. These neurotoxins are potent inhibitors of calcium-dependent neurotransmitter secretion of neuronal cells and are among the strongest toxins known to man. The lethal dose in humans lies between 0.1 ng and 1 ng per kilogram of body weight.
Oral ingestion of botulinum toxin via contaminated food or generation of botulinum toxin in wounds can cause botulism, which is characterised by paralysis of various muscles. Paralysis of the breathing muscles can cause death of the affected individual.
Although both botulinum neurotoxin (BoNT) and tetanus neurotoxin (TeNT) function via a similar initial physiological mechanism of action, inhibiting neurotransmitter release from the axon of the affected neuron into the synapse, they differ in their clinical response. While the botulinum toxin acts at the neuromuscular junction and other cholinergic synapses in the peripheral nervous system, inhibiting the release of the neurotransmitter acetylcholine and thereby causing flaccid paralysis, the tetanus toxin, which is transcytosed into central neurons, acts mainly in the central nervous system, preventing the release of the inhibitory neurotransmitters GABA (gamma-aminobutyric acid) and glycine by degrading the protein synaptobrevin. The consequent overactivity of spinal cord motor neurons causes generalized contractions of the agonist and antagonist musculature, termed a tetanic spasm (rigid paralysis).
While the tetanus neurotoxin exists in one immunologically distinct type, the botulinum neurotoxins are known to occur in seven different immunogenic serotypes, termed BoNT/A through BoNT/H with further subtypes. Most Clostridium botulinum strains produce one type of neurotoxin, but strains producing multiple toxins have also been described.
Botulinum and tetanus neurotoxins have highly homologous amino acid sequences and show a similar domain structure. Their biologically active form comprises two peptide chains, a light chain of about 50 kDa and a heavy chain of about 100 kDa, linked by a disulfide bond. A linker or loop region, whose length varies among different clostridial toxins, is located between the two cysteine residues forming the disulfide bond. This loop region is proteolytically cleaved by an unknown clostridial endoprotease to obtain the biologically active toxin.
The molecular mechanism of intoxication by TeNT and BoNT appears to be similar as well: entry into the target neuron is mediated by binding of the C-terminal part of the heavy chain to a specific cell surface receptor; the toxin is then taken up by receptor-mediated endocytosis. The low pH in the so formed endosome then triggers a conformational change in the clostridial toxin which allows it to embed itself in the endosomal membrane and to translocate through the endosomal membrane into the cytoplasm, where the disulfide bond joining the heavy and the light chain is reduced. The light chain can then selectively cleave so called SNARE-proteins, which are essential for different steps of neurotransmitter release into the synaptic cleft, e.g. recognition, docking and fusion of neurotransmitter-containing vesicles with the plasma membrane. TeNT, BoNT/B, BoNT/D, BoNT/F, and BoNT/G cause proteolytic cleavage of synaptobrevin or VAMP (vesicle-associated membrane protein), BoNT/A and BoNT/E cleave the plasma membrane-associated protein SNAP-25, and BoNT/C cleaves the integral plasma membrane protein syntaxin and SNAP-25.
In Clostridium botulinum, the botulinum toxin is formed as a protein complex comprising the neurotoxic component and non-toxic proteins. The accessory proteins embed the neurotoxic component thereby protecting it from degradation by digestive enzymes in the gastrointestinal tract. Thus, botulinum neurotoxins of most serotypes are orally toxic. Complexes with, for example, 450 kDa or with 900 kDa are obtainable from cultures of Clostridium botulinum.
In recent years, botulinum neurotoxins have been used as therapeutic agents, for example in the treatment of dystonias and spasms, and have additionally been used in cosmetic applications, such as the treatment of fine wrinkles. Preparations comprising botulinum toxin complexes are commercially available, e.g. from Ipsen Ltd (Dysport®) or Allergan Inc. (Botox®). A high purity neurotoxic component, free of any complexing proteins, is for example available from Merz Pharmaceuticals GmbH, Frankfurt (Xeomin).
Clostridial neurotoxins are usually injected into the affected muscle tissue, bringing the agent close to the neuromuscular end plate, i.e. close to the cellular receptor mediating its uptake into the nerve cell controlling said affected muscle. Various degrees of neurotoxin spread have been observed. The neurotoxin spread is thought to depend on the injected amount and the particular neurotoxin preparation. It can result in adverse side effects such as paralysis in nearby muscle tissue, which can largely be avoided by reducing the injected doses to the therapeutically relevant level. Overdosing can also trigger the immune system to generate neutralizing antibodies that inactivate the neurotoxin preventing it from relieving the involuntary muscle activity. Immunologic tolerance to botulinum toxin has been shown to correlate with cumulative doses.
Clostridial neurotoxins display variable durations of action that are serotype specific. The clinical therapeutic effect of BoNT/A lasts approximately 3 months for neuromuscular disorders and 6 to 12 months for hyperhidrosis. The effects of BoNT/E, on the other hand, last about 4 weeks. One possible explanation for the divergent durations of action might be the distinct subcellular localizations of BoNT serotypes. The protease domain of BoNT/A light chain localizes in a punctate manner to the plasma membrane of neuronal cells, co-localizing with its substrate SNAP-25. In contrast, the short-duration BoNT/E serotype is cytoplasmic. Membrane association might protect BoNT/A from cytosolic degradation mechanisms allowing for prolonged persistence of BoNT/A in the neuronal cell.
The longer lasting therapeutic effect of BoNT/A makes it preferable for certain clinical uses and in particular for certain cosmetic uses compared to the other serotypes, for example serotypes B, C1, D, E, F, G and H. On the other hand, it might be advantageous in certain scenarios to decrease the duration of the therapeutic effect of a botulinum neurotoxin in order to reduce the duration of muscle paralysis.
WO 2011/000929 and WO 2013/068476 describe neurotoxins exhibiting a shortened biological activity. In brief, the applications describe polypeptides comprising at least one E3 ligase recognition motif in the light chain, wherein said E3 ligase recognition motif is preferably a binding motif for the E3 ligase MDM2. Section [0006] of WO 2013/068476 generically lists a number of indications, which could potentially benefit from the application of modified neurotoxins with decreased duration of effect.
In particular, WO 2013/068476 describes variants of BoNT/E (SEQ ID NOs: 52 and 80 in WO 2013/068476), which were shown to have a duration of effect, which was decreased by about 25% compared to wild-type BoNT/E in a cell culture assay.
Despite the progress that has been made in the past in the treatment of indications that benefit from the intermittent paralysis of muscles, there is still a strong demand to further improve the therapeutic options available to the practitioner in the art, in particular in light of the fact that it might be desirable in certain indications, after an initial requirement for paralysing one or more muscles in such indication, to achieve an earlier recovery of muscle activity to assist the patient being treated in getting back to his or her normal life. To date, such aspects have not been addressed satisfactorily.
It was an object of the invention to provide novel uses for recombinant clostridial neurotoxins exhibiting a decreased duration of effect, and in particular uses for the treatment of patients suffering from a limited range of muscle extension, in particular from muscle contracture, more particularly from flexion contracture, in particular flexion contracture of the knee, and more particularly to improve the treatment of such patients having experienced total or partial knee arthroplasty.
The naturally occurring botulinum toxin serotypes display highly divergent durations of effect, with BoNT/A exhibiting the longest persistence, and BoNT/E exhibiting a comparatively short persistence. In order to broaden the applicability of botulinum neurotoxins, variants of BoNT/E have been created that exhibit a shorter duration of effect (see in particular WO 2013/068476).
Surprisingly, it has been identified that the variants disclosed in WO 2013/068476 might advantageously be used in particular situations, for which no satisfactory solution has been available so far.
Thus, the present invention relates to a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1, or SEQ ID NO: 2, or a functionally active variant thereof, for use in the treatment of a patient suffering from a limited range of muscle extension.
In a second aspect, the present invention relates to a method of treating a patient suffering from a limited range of muscle extension, comprising the step of treating said patient with a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1, or SEQ ID NO: 2, or a functionally active variant thereof.
The present invention may be understood more readily by reference to the following detailed description of the invention and the examples included therein.
Thus, the present invention relates to a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1, or SEQ ID NO: 2, or a functionally active variant thereof, for use in the treatment of a patient suffering from a limited range of muscle extension.
In a second aspect, the present invention relates to a method of treating a patient suffering from a limited range of muscle extension, comprising the step of treating said patient with a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1, or SEQ ID NO: 2, or a functionally active variant thereof.
In the context of the present invention, the term “limited range of muscle extension” refers to a muscle that has temporarily lost its ability to achieve full relaxation and extension, i.e. a muscle showing an extension deficit or extension lag. Such a limited range of muscle extension may be the result of a period of non-use or limited use of normal, physiological muscle activity, which may be caused by an underlying pathological condition and/or pain sensations the patient experiences when using a muscle or joint including in case of an underlying arthrosis, arthritis or other inflammatory condition, in case of overstraining, and/or incomplete rehabilitation after injuries or surgical procedures, which may result in attempts to reduce or avoid moving the afflicted joint and/or in using a relieving posture, which may additionally contribute to a reduced muscle activity and subsequent limitation of muscle extension.
Over time, a limitation of muscle extension may result in a contracture of that muscle.
Thus, in particular embodiments, the present invention relates to a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1, or SEQ ID NO: 2, or a functionally active variant thereof, for use in the treatment of a patient suffering from muscle contracture.
In the context of the present invention, the term “muscle contracture” relates to a shortening of the muscle and its tendons, resulting in reduced flexibility.
Muscle contracture may limit the range of motion for a joint next to such contracted muscle, and which may ultimately result in flexion contracture. Similarly, such a condition may be the result of a longer term immobilization of a joint, for example in case of long lasting diseases. This leads to rigidity in the affected muscles and inability to perform physical therapy without pain.
Thus, in particular embodiments, the present invention relates to a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1, or SEQ ID NO: 2, or a functionally active variant thereof, for use in the treatment of a patient suffering from flexion contracture.
In the context of the present invention, the term “flexion contracture” refers to a situation caused by a shortening of muscle tissues and tendons, forcing a joint into a flexed position and holding it there. Flexion contracture results in a limited range of movement in the affected joint, which may no longer be fully straightened. The range of motion in the afflicted joint is restricted and patients are impaired in daily activities. In the case of a flexion contracture of a knee, this may include an impairment of activities like walking, rising from a chair, bike-riding etc.
In theory, by injecting a locally-acting muscle relaxant, the contracture of the affected muscles could temporarily be dissolved.
Therefore, patients with flexion contracture have been treated with commercially available botulinum toxin [Seyler T M, Smith B P, Marker D R, Ma J, Shen J, Smith T L, Mont M A, Kolaski K, Koman L A: Botulinum Neurotoxin as a Therapeutic Modality in Orthopaedic Surgery: More Than Twenty Years of Experience. J Bone Joint Surg Am 2008; 90 Suppl 4:133-45].
However, the long-lasting effect of BoNT/A appears to be not permitting its use in patients, since the affected muscles are essential for the stabilization of the joint, and it is believed that immobilization of muscles involved in stabilization and movement of a joint such as the knee may ultimately lead to muscle atrophy and in particular to stiffening of the afflicted joint. Furthermore, immobilization of the muscles hinders a patient to perform physical therapy to get the full range of motion of the joint.
Surprisingly, it was identified that botulinum neurotoxins with a short duration of action are able to overcome the problems associated with therapeutic interventions, including physiotherapy, used in the prior art. The proteins having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 are local muscle relaxants with an onset of effect within a day and an estimated duration of effect of about 4 weeks, which is even shorter than the duration of effect of wild-type BoNT/E. Since these proteins have a shorter duration of action than BoNT/A, a relaxation of the affected muscles is expected to last only 2 to 4 weeks. This enables patients to start physiotherapy earlier and train and strengthen those muscles conferring dynamic stability to the affected joint before these muscles undergo atrophy as inevitably occurs after treatment with Botulinum toxins with a long duration of action such as BoNT/A with 12 weeks. As a result of earlier muscle recovery a reduction of overall physiotherapy is expected since the patient may earlier achieve the ability to return to activities which require an effective use of the afflicted joint.
Thus, in another particular embodiment, the present invention relates to a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1, or SEQ ID NO: 2, or a functionally active variant thereof, for use in the treatment of a patient suffering from a patellofemoral pain syndrome, wherein such syndrome is due to lateral malposition of the patella in connection with muscular dysbalance between an overactive M. vastus lateralis and a weak M. vastus medialis (T. Gisler: Dehnung des M. quadriceps femoris aus anatomisch-physiologischer Sicht. Schweizerische Zeitschrift für Sportmedizin and Sporttraumatologie 60 (2012) 116-124).
In particular embodiments, said treatment comprising the treatment of the M. quadriceps femoris.
Further the duration of botulinum toxin specific side effects will be reduced due to the shorter duration of the toxin.
In the context of the present invention, the term “functionally active variant” refers to a neurotoxin, in particular a recombinant neurotoxin, that differs in the amino acid sequence and/or the nucleic acid sequence encoding the amino acid sequence from the botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2, but is still functionally active. In the context of the present invention, the term “functionally active” refers to the property of such recombinant clostridial neurotoxin variant to (i) achieve muscle paralysis to at least 50%, particularly to at least 60%, at least 70%, at least 80%, and most particularly at least 90% of the muscle paralysis achieved with the same amount of a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2, and (ii) achieve such muscle paralysis for a duration of time that is at maximum 10% shorter or longer, particularly at maximum 5% shorter or longer than the duration of paralysis achieved by a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 (i.e. which shows between 90% and 110% of the duration of paralysis, particularly between 95% and 105% of the duration of paralysis achieved by a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2).
On the protein level, a functionally active variant will maintain key features of the corresponding parental clostridial neurotoxin, such as key residues for the endopeptidase activity in the light chain, or key residues for the attachment to the neurotoxin receptors or for translocation through the endosomal membrane in the heavy chain, but may contain one or more mutations comprising a deletion of one or more amino acids of the corresponding clostridial neurotoxin, an addition of one or more amino acids of the corresponding clostridial neurotoxin, and/or a substitution of one or more amino acids of the corresponding clostridial neurotoxin. Particularly, said deleted, added and/or substituted amino acids are consecutive amino acids. According to the teaching of the present invention, any number of amino acids may be added, deleted, and/or substituted, as long as the functionally active variant remains biologically active as defined above. For example, 1, 2, 3, 4, 5, up to 10, up to 15, up to 25, up to 50, up to 100, up to 200, up to 400, up to 500 amino acids or even more amino acids of a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 may be added, deleted, and/or substituted. This neurotoxin fragment may contain an N-terminal, C-terminal, and/or one or more internal deletion(s).
In another embodiment, the functional variant of a clostridial neurotoxin additionally comprises a signal peptide. Usually, said signal peptide will be located at the N-terminus of the neurotoxin. Many such signal peptides are known in the art and are comprised by the present invention. In particular, the signal peptide results in transport of the neurotoxin across a biological membrane, such as the membrane of the endoplasmic reticulum, the Golgi membrane or the plasma membrane of a eukaryotic or prokaryotic cell. It has been found that signal peptides, when attached to the neurotoxin, will mediate secretion of the neurotoxin into the supernatant of the cells. In certain embodiments, the signal peptide will be cleaved off in the course of, or subsequent to, secretion, so that the secreted protein lacks the N-terminal signal peptide, is composed of separate light and heavy chains, which are covalently linked by disulfide bridges, and is proteolytically active.
In particular embodiments, the functional variant has in its clostridium neurotoxin part a sequence identity of at least 40%, at least 50%, at least 60%, at least 70% or most particularly at least 80%, and a sequence homology of at least 60%, at least 70%, at least 80%, at least 90%, or most particularly at least 95% to the corresponding part of a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2. Methods and algorithms for determining sequence identity and/or homology, including the comparison of variants having deletions, additions, and/or substitutions relative to a parental sequence, are well known to the practitioner of ordinary skill in the art. On the DNA level, the nucleic acid sequences encoding the functional homologue and the parental clostridial neurotoxin may differ to a larger extent due to the degeneracy of the genetic code. It is known that the usage of codons is different between prokaryotic and eukaryotic organisms. Thus, when expressing a prokaryotic protein such as a clostridial neurotoxin, in a eukaryotic expression system, it may be necessary, or at least helpful, to adapt the nucleic acid sequence to the codon usage of the expression host cell, meaning that sequence identity or homology may be rather low on the nucleic acid level.
In the context of the present invention, the term “variant” refers to a neurotoxin that is a chemically, enzymatically, or genetically modified derivative of a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2. A chemically modified derivative may be one that is modified by pyruvation, phosphorylation, sulfatation, lipidation, pegylation, glycosylation and/or the chemical addition of an amino acid or a polypeptide comprising between 2 and 100 amino acids, including modification occurring in the eukaryotic host cell used for expressing the derivative. An enzymatically modified derivative is one that is modified by the activity of enzymes, such as endo- or exoproteolytic enzymes, including modification by enzymes of the eukaryotic host cell used for expressing the derivative. As pointed out above, a genetically modified derivative is one that has been modified by deletion or substitution of one or more amino acids contained in, or by addition of one or more amino acids (including polypeptides comprising between 2 and about 100 amino acids) to, the amino acid sequence of said clostridial neurotoxin. Methods for designing and constructing such chemically or genetically modified derivatives and for testing of such variants for functionality are well known to anyone of ordinary skill in the art.
In the context of the present invention, the term “recombinant neurotoxin” refers to a composition comprising a clostridial neurotoxin that is obtained by expression of the neurotoxin in a heterologous cell such as E. coli, and including, but not limited to, the raw material obtained from a fermentation process (supernatant, composition after cell lysis), a fraction comprising a clostridial neurotoxin obtained from separating the ingredients of such a raw material in a purification process, an isolated and essentially pure protein, and a formulation for pharmaceutical and/or aesthetic use comprising a clostridial neurotoxin and additionally pharmaceutically acceptable solvents and/or excipients.
In the context of the present invention, the term “comprises” or “comprising” means “including, but not limited to”. The term is intended to be open-ended, to specify the presence of any stated features, elements, integers, steps or components, but not to preclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof. The term “comprising” thus includes the more restrictive terms “consisting of” and “consisting essentially of”.
In the context of the present invention, the term “botulinum neurotoxin subtype E” refers to a particular neurotoxin found in and obtainable from Clostridium botulinum having a sequence shown in SEQ ID NO: 82 of WO 2013/068476.
In particular embodiments, said functionally active variant has a persistence that is at maximum 5% shorter or longer than the duration of paralysis achieved by a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2.
Without wishing to be bound by theory, the recombinant clostridial neurotoxins of the present invention might show decreased biological half-life, increased degradation rates, increased diffusion rates, decreased uptake by neuronal cells, and/or modified intracellular translocation rates, in each case relative to wild-type botulinum neurotoxin of subtype E (BoNT/E).
Of particular relevance is flexion contracture of the knee. Thus, in a particular embodiment, the patient is suffering from a flexion contracture of the knee.
Flexion contracture is a particularly important complication in the case of patients undergoing a Total Knee Arthroplasty.
Thus, in a particular embodiment, the patient is suffering from a flexion contracture of the knee after Total Knee Arthroplasty.
In the context of the present invention, the term “Total Knee Arthroplasty” (TKA) refers to a surgery, wherein the weight-bearing surfaces of the knee joint are replaced by artificial components in order to relieve pain and disability associated with the diseased joint.
Patients who received a TKA often develop a flexion contracture in the hamstrings or other muscles moving the knee joint.
Seyler et al. 2008 [Seyler T M, Smith B P, Marker D R, Ma J, Shen J, Smith T L, Mont M A, Kolaski K, Koman L A: Botulinum Neurotoxin as a Therapeutic Modality in Orthopaedic Surgery: More Than Twenty Years of Experience. J Bone Joint Surg Am 2008; 90 Suppl 4:133-45] published the improvement of pain and range of motion after injection of commercially available botulinum toxin (onabotulinumtoxinA) in patients with flexion contracture after TKA.
In particular such embodiments, said patient suffers from muscle contracture of one or more muscles selected from the list of: biceps femoris (lateral hamstring), semitendinosus, semimembranosus (medial hamstrings), and gastrocnemius
In particular embodiments, the patient is suffering from a flexion contracture of the elbow.
In particular such embodiments, said patient suffers from muscle contracture of one or more muscles selected from the list of: biceps brachii, and brachialis muscle.
In particular embodiments, the patient is suffering from a flexion contracture of the shoulder.
In particular such embodiments, said patient suffers from muscle contracture of one or more muscles selected from the list of: infraspinatus, pectoralis, subscapularis teres major, and latissimus dorsi muscle.
In particular embodiments, the patient is suffering from a flexion contracture of the hip.
In particular such embodiments, said patient suffers from muscle contracture of one or more muscles selected from the list of: tensor fascia lata muscle, and rectus femoris muscle adductor muscle.
In particular embodiments, the patient is suffering from a flexion contracture of the ankle.
In particular such embodiments, said patient suffers from muscle contracture of one or more muscles selected from the list of: foot:triceps surae (gastrocnemius, and plantaris muscle).
In particular embodiments, said muscle contracture cannot be corrected only by correction of the connective tissue of said one or more muscles or by correcting connective tissue associated with the joint directly that causes muscle contracture.
In particular embodiments, said treatment comprises the administration of said botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2, or of said functionally active variant thereof, to one or more muscles selected from the list of: long head of biceps femoris, semitendinosus, semimembranosus (hamstrings), gastrocnemius, and soleus.
In particular embodiments, muscle paralysis by a botulinum neurotoxin of more than 5 weeks, in particular of more than 4 weeks, and more particularly of more than 3 weeks, is contraindicated and/or deemed to be associated with negative impact on overall treatment success, particularly due to high likelihood of increased muscle atrophy.
Treatment of flexion contracture in accordance with the present invention may make surgery of the afflicted joint or any manipulation under anesthesia unnecessary, for example by permitting physiotherapeutic strengthening of the muscles stabilizing the joint, or may at least be able to delay such surgery, for example in the case of young patients. Additionally, a treatment of flexion contracture in accordance with the present invention prior to surgery of the afflicted joint may increase the success rate in rehabilitation, since a flexion contracture in existence prior to surgery is known to be a risk factor for the development of flexion contracture thereafter.
Thus, in particular embodiments, a patient suffering from a limited range of muscle extension or from flexion contracture is treated prior to a planned surgery of the afflicted joint.
Knee pain is a common complaint; it can be caused by extreme overuse, osteoarthritis, an acute injury or from incomplete or unsuccessful rehabilitation after surgery or injury. Often pain is chronic and gets worse over time. People with knee pain often favor the painful knee and as a result loose knee range of motion and develop flexion contracture (functional loss of knee extension).
Patients with a knee flexion contracture experience rehabilitation difficulties because a knee flexion contracture is difficult to exercise. The relaxation of the flexors with botulinum neurotoxin subtype E with its fast onset of action and short duration of action having a sequence according to SEQ ID NO: 1 will facilitate physiotherapy and make it more effective without the risk of weakening the flexors by immobilizing them for too long a time. This is a new non-operative treatment modality to treat patients with a restricted range of motion by improving function and thus reducing pain.
A patient undergoes a surgery after a distal femur fracture, followed by immobilization of the knee for three weeks. As a result, the patient shows a flexion contracture of more than 10 degrees and is not able to start physiotherapy due to extreme pain.
Within 3 days after injection of a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 the patient is able to perform physiotherapy.
Knee flexion contracture (the inability to fully straighten the knee due to pain and stiffness) is an unwanted complication after total knee arthroplasty. Flexion contracture leads to functional deficits and persistent pain. The injection of botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 leads to a temporary neuromuscular transmitter blockade with a fast onset of action and a short duration of action. Due to relaxation of the flexors physiotherapy becomes more effective and accelerates the progress of rehabilitation. The fast onset and short duration of action can be well aligned with physical therapy and does not impede the strengthening of any of the muscles involved.
A patient undergoes a TKA after osteoarthritis. Despite extensive physiotherapy he is not able to complete the swing phase of gait, to ascend or descend stair and to rise from a standard chair. Further he suffers from extreme pain. The diagnosis is a flexion contracture of more than 5 degrees.
Within 3 days after injection of a botulinum neurotoxin subtype E with reduced persistence having a sequence according to SEQ ID NO: 1 the patient is able to perform physiotherapy. After 4 weeks the patient has a full range of motion in the affected knee, is able to use stairs and has no other limitations of daily activities. No further physiotherapy or pain medication is necessary.
| Number | Date | Country | Kind |
|---|---|---|---|
| 14002053.8 | Jun 2014 | EP | regional |
| 15000529.6 | Feb 2015 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2015/001188 | 6/12/2015 | WO | 00 |
